Find Clinical Trials

Pembrolizumab in Treating Patients with Triple-Negative Breast Cancer

Principal Investigator: David Hufnagel, DO

Aspirin in Preventing Recurrence of Cancer in Patients with Node Positive HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

Principal Investigator: David Hufnagel, DO

Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

Principal Investigator: David Hufnagel, DO

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

Principal Investigator: Michael Wahl, MD

Genetic Testing in Screening Patients with Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Principal Investigator: David Hufnagel, DO

Crizotinib in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Principal Investigator: David Hufnagel, DO

Erlotinib Hydrochloride in Treating Patients with Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

Principal Investigator: David Hufnagel, DO

Nivolumab After Surgery and Chemotherapy in Treating Patients with Stage IB-IIIA Non-Small Cell Lung Cancer (ANVIL)

Principal Investigator: David Hufnagel, DO

Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Principal Investigator: Michael Wahl, MD

Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

Principal Investigator: David Hufnagel, DO

A Phase 3 Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab

A Phase 3, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/ Refractory Multiple Myeloma (RRMM) (DREAMM3)

Principal Investigator: Keith Goldstein, MD

NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma

Principal Investigator: Wei Bai, MD

Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

Principal Investigator: David Hufnagel, DO

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients with Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin

Principal Investigator: David Hufnagel, DO

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

Principal Investigator: David Hufnagel, DO

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (TALAPRO-2)

Principal Investigator: Keith Goldstein, MD

Multi-Centre, Multi-National, Open Label, Safety Study of Etripamil Nasal Spray for Patients with Paroxysmal Supraventricular Tachycardia

Principal Investigator: Jeff Hsing, MD

Exercise and Insulin Signaling in Human Skeletal Muscle

Samaritan Health Services Principal Investigators: Craig Graham, MD, Nicholas Phillips, MD, and Josh Lenhof, DO

Oregon State University Principal Investigators: Sean Newsom, PhD, and Matthew Robinson, PhD